Drug Trial Radar · NCT06610682
A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Apr 7, 2025
Primary completion
Jun 30, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Fore Biotherapeutics; Ivy Brain Tumor Foundation; Incyte Corporation
- First posted
- Sep 24, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline (defined as C1D1) and over time in response to treatment with plixorafenib alone or in combination with retifanlimab in patients with BRAF-V600E mutant glioma refractory to prior therapies.
Conditions
- BRAF V600E Mutation
Interventions
PlixorafenibDrug
Patients will start the study drug (plixorafenib 900mg daily 30 minutes after a full meal or meal supplement) 7-28 days post-operatively, when clinically stable. Patients will take the drug daily by mouth continuously for 28-day cycles until progressive disease or up to 24 cycles. MRI will be performed post-operatively (between surgery and start of study drug) for evaluation of measurable disease, at the beginning of Cycle 2, then at the beginning of every odd cycle. Blood and CSF samples will be obtained on day of surgery, C1D1 (baseline), pre-C2 (week 4) and with every odd cycle up to and including C7 and EOT.
RetifanlimabDrug
Investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline and over time in response to treatment with plixorafenib alone or in combination with retifanlimab in patients with BRAF-V600E mutant glioma refractory to prior therapies.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Detection rate of BRAF-V600E ctDNA in CSF and/or plasmaTime frame: surgery, baseline (C1D1) and pre-cycle 2 (week 4)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Johns Hopkins
Baltimore, Maryland · Recruiting
NYU Langone Health Perlmutter Cancer Center Ambulatory Care Center
New York, New York · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.